Market Talking
Despite investors’ concerns over ResMed’s future sales, analysts remain positive. After the shares dipped today, analyst Mathieu Chevrier from Citi reiterated a Buy rating on RMD stock, predicting an upside of 28.5%.
Similarly, Morgan Stanley analyst Sean Laaman estimates another 20% upside potential in the shares and maintains a Buy recommendation.
Laaman believes that the CPAP market might not be as vulnerable as some investors perceive, despite these positive results. He added that the increased awareness of sleep apnea will likely lead to more individuals seeking better ways to manage their health.